Sphingosine

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology

Retrieved on: 
Thursday, October 20, 2022

About RecludixRecludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company was founded by members of Blueprint Medicines’ founding scientific team and its management team includes industry veterans with a track record of success in the discovery, development and commercialization of multiple oncology drugs. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins -- STAT3 and STAT6 -- where abnormal activation is found in numerous cancer types, such as multiple leukemias and lymphomas, as well as inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, inflammatory bowel disease, and others. The company is advancing three other programs to undisclosed targets that also play a significant role in both cancer and autoimmune diseases. For more information, please visit the company’s website at https://recludixpharma.com.

Key Points: 
  • Dr. Smith has more than 15 years of drug discovery experience primarily focused on the treatment of inflammatory and autoimmune diseases.
  • Dr. Smith was most recently at Connect Biopharma as the vice president of discovery biology responsible for the prioritization, planning and execution of their preclinical discovery pipeline.
  • Earlier in his career, Dr. Smith was a senior scientist at UCB focused on novel biologics-based treatment strategies for inflammatory diseases.
  • The company is advancing three other programs to undisclosed targets that also play a significant role in both cancer and autoimmune diseases.

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Retrieved on: 
Friday, June 17, 2022

The Phase 2a segment of the FMX 114 study is designed to evaluate four weeks of FMX114 treatment in patients with AD compared to vehicle control.

Key Points: 
  • The Phase 2a segment of the FMX 114 study is designed to evaluate four weeks of FMX114 treatment in patients with AD compared to vehicle control.
  • We look forward to reporting the results of the Phase 2a segment of the study in approximately 6 to 8 weeks.
  • About The FMX114 2a study ( VY2021-01, ClinicalTrials.gov Identifier: NCT04927572 )
    The Phase 2a segment of the study is a randomized, double-blinded trial, designed to compare the safety and efficacy of FMX114 gel with vehicle gel.
  • As in the Phase 1b study, the enrollment criteria specifies that subjects must have two comparable target AD lesions for treatment upon entry.

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

Retrieved on: 
Thursday, April 7, 2022

FMX114 has the potential to be the first topical combination product for the treatment of AD.

Key Points: 
  • FMX114 has the potential to be the first topical combination product for the treatment of AD.
  • Efficacy data for the Phase 1b segment of the trial was assessed based on the absolute and percent change relative to baseline in ADSI score at week 2.
  • About The FMX114 Phase 1b/2a study ( VY2021-01, ClinicalTrials.gov Identifier: NCT04927572 )
    The Phase 1b/2a study is a randomized, double-blinded trial designed to compare the safety and efficacy of FMX114 gel with vehicle gel.
  • According to Symphony Health data, there were over 7 million prescriptions written in 2019 alone for the treatment of AD.

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Retrieved on: 
Tuesday, October 19, 2021

BRIDGEWATER, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has enrolled the first patient in its Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).

Key Points: 
  • BRIDGEWATER, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that it has enrolled the first patient in its Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).
  • Dr. Iain Stuart, Chief Scientific Officer of VYNE, stated, With FMX114, VYNE is further leveraging our extensive drug development capabilities by providing another unique targeted therapy with difficult-to-formulate active ingredients.
  • FMX114 is an important addition to VYNEs clinical development pipeline, and we are pleased to have enrolled the first patient in this trial, said David Domzalski, Chief Executive Officer of VYNE.
  • For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.

Global Sphingosine 1-Phosphate Receptor (S1PR) Drugs Development Market Report 2021: Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 29, 2021

b'The "Sphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nSphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021 provides in depth analysis on Sphingosine 1-Phosphate Receptor (S1PR) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "Sphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nSphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021 provides in depth analysis on Sphingosine 1-Phosphate Receptor (S1PR) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics development and features dormant and discontinued projects.
  • The report analyses the pipeline products across relevant therapy areas under development targeting Sphingosine 1-Phosphate Receptor (S1PR).\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which include Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics.\n'

Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm

Retrieved on: 
Tuesday, April 27, 2021

\xe2\x80\x9cThat is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory process in patients with moderate COVID-19.

Key Points: 
  • \xe2\x80\x9cThat is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory process in patients with moderate COVID-19.
  • That will be followed by a review of the final clinical data on completion of treatment of the final patient.
  • Veyonda\xc2\xae is the Company\xe2\x80\x99s first pipe-line drug candidate currently in Phase 2 clinical trialing.
  • Veyonda has two main drug actions \xe2\x80\x93 a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signaling.

Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19

Retrieved on: 
Wednesday, April 29, 2020

The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the companys proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors.

Key Points: 
  • The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the companys proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors.
  • Significantly, elevated levels of inflammatory cytokines, particularly IL-6, are reported to be associated with the development of respiratory failure in COVID-19 patients.
  • Elazar Rabbani, Ph.D., CEO of Enzo Biochem, Inc. commented: Enzos response to the COVID-19 pandemic has been multi-faceted.
  • The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.